Showing 8361-8370 of 8647 results for "".
- Spectralis High Magnification Module Receives FDA Clearancehttps://modernod.com/news/spectralis-high-magnification-module-receives-fda-clearance/2479726/Heidelberg Engineering announced it has received FDA clearance for its Spectralis High Magnification Module. This new module consists of a highly innovative lens and software upgrade that will be available for new and
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi
- EyeMD EMR Healthcare Systems to Debut its EyeMD Electronic Medical Records 2.0 Releasehttps://modernod.com/news/eyemd-to-debut-its-eyemd-electronic-medical-records-2-0-release/2479739/EyeMD EMR Healthcare Systems, a provider of electronic medical records software designed specifically for ophthalmologists, announced the debut of EyeMD EMR 2.0 at the 2018 American Academy of Ophthalmology’s Annual Meeting in Chicago. “EyeMD EMR 2.0 is the result of years of research and
- Reay H. Brown, MD, Joins Sight Sciences as Chief Medical Officerhttps://modernod.com/news/reay-h-brown-md-joins-sight-sciences-as-chief-medical-officer/2479741/Sight Sciences announced that Reay H. Brown, MD, has joined the company as Chief Medical Officer (CMO). Dr. Brown is one of the most prolific inventors and innovators in the history of surgical glaucoma. He was the original inventor of trabecular microbypass stenting, which has served as t
- Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy Studyhttps://modernod.com/news/eylea-injection-improves-diabetic-retinopathy-and-reduces-vision-threatening-complications-in-phase-3-trial/2479745/Regeneron Pharmaceuticals announced that the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe and severe non-proliferative diabetic retinopathy (NPDR) met its 1-year (52-week) primary endpoint and key secondary endpoints. On the primary end
- New CorneaGen Interactive Education Program To Offer Free Online Training for Surgeonshttps://modernod.com/news/new-corneagen-interactive-education-program-to-offer-free-online-training-for-all-surgeons/2479755/CorneaGen is adding interactive, online courses to its free education program for surgeons around the world. Utilizing an online platform designed for universities, CorneaGen will offer instruction in cutting-edge procedures such as Nano-Thin DSEK and best practices for using transplant devices.
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- Cell Care Therapeutics Raises $4.3 Million in Seed Fundinghttps://modernod.com/news/cell-care-therapeutics-raises-4-3-million-in-seed-funding/2479765/Cell Care Therapeutics announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to ad
- Oxurion Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Projecthttps://modernod.com/news/oxurion-extends-partnership-with-retina-global-in-support-of-bolivian-diabetic-retinopathy-boldr-project/2479770/Oxurion NV announced it is extending its partnership with Retina Global, an international nonprofit organization focused on sustainable outcomes to retinal disease management in underserved areas around the world. Oxurion will support Retina Global’s Bolivian Diabetic Retinopathy Project (BOLDR),
- Kala Pharmaceuticals Submits NDA to FDA for KPI-121 0.25% for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-submits-nda-to-fda-for-kpi-121-0-25-for-dry-eye-disease/2479782/Kala Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. There are an estimated